Laekna's LAE120, a novel allosteric USP1 inhibitor, receives FDA IND approval for treating advanced solid tumors, demonstrating robust anti-tumor activity in various xenograft models.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.